- Home
- GOGL vs AZTA Comparison
GOGL vs AZTA Comparison
Compare GOGL & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOGL
- AZTA
- Stock Information
- Founded
- GOGL N/A
- AZTA 1978
- Country
- GOGL Bermuda
- AZTA United States
- Employees
- GOGL N/A
- AZTA N/A
- Industry
- GOGL Marine Transportation
- AZTA Industrial Machinery/Components
- Sector
- GOGL Consumer Discretionary
- AZTA Technology
- Exchange
- GOGL Nasdaq
- AZTA Nasdaq
- Market Cap
- GOGL 1.9B
- AZTA 1.8B
- IPO Year
- GOGL 1997
- AZTA 1995
- Fundamental
- Price
- GOGL $7.16
- AZTA $25.25
- Analyst Decision
- GOGL Hold
- AZTA Buy
- Analyst Count
- GOGL 2
- AZTA 3
- Target Price
- GOGL $11.25
- AZTA $57.00
- AVG Volume (30 Days)
- GOGL 5.2M
- AZTA 876.0K
- Earning Date
- GOGL 05-21-2025
- AZTA 05-07-2025
- Dividend Yield
- GOGL 14.94%
- AZTA N/A
- EPS Growth
- GOGL 99.39
- AZTA N/A
- EPS
- GOGL 1.12
- AZTA N/A
- Revenue
- GOGL $968,420,000.00
- AZTA $662,108,000.00
- Revenue This Year
- GOGL N/A
- AZTA N/A
- Revenue Next Year
- GOGL $16.40
- AZTA $5.44
- P/E Ratio
- GOGL $6.41
- AZTA N/A
- Revenue Growth
- GOGL 9.33
- AZTA 5.36
- 52 Week Low
- GOGL $6.27
- AZTA $25.36
- 52 Week High
- GOGL $15.77
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- GOGL 44.01
- AZTA 27.55
- Support Level
- GOGL $6.94
- AZTA $25.36
- Resistance Level
- GOGL $7.49
- AZTA $27.89
- Average True Range (ATR)
- GOGL 0.41
- AZTA 2.31
- MACD
- GOGL 0.01
- AZTA -0.23
- Stochastic Oscillator
- GOGL 41.78
- AZTA 5.13
About GOGL Golden Ocean Group Limited
Golden Ocean Group Ltd is a Bermuda-based dry bulk shipping company. Its business involves the transportation of dry bulk cargo including ores, coal, grains and fertilizers through its fleet of owned and chartered vessels, bareboat vessels, commercial management vessels and new buildings are chartered-out on fixed rate time charters and index-linked time charter contracts.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.